MIEP方案治疗复发或难治非霍奇金淋巴瘤疗效报告

Mitoxantrone, Ifosphamide, Etoposide and Prednisone Regimen in the Treatment of Relapsed or Stubborn Non-Hodgkin's Lymphoma

目的 观察MIEP化疗方案治疗复发或难治非霍奇金淋巴瘤 (NHL)临床疗效和毒副作用。方法 3 5例复发或难治NHL患者给予米托蒽醌 (MIT) 10mg/m2 静滴 ,d1;异环磷酰胺 (IFO) 1 2g/m2 静滴 ,d1～ 4,美司那 (Mesna) 40 0mg用IFO后 0、4、8h静推 ;依托泊甙 (VP 16) 65mg/m2 静滴 ,d1～ 4;强的松 (PRED) 10 0mg口服 ,d1～ 5。 2 1～ 2 8天为一周期 ,至少 3个周期。结果 MIEP方案化疗的疗效CR 2 8 6% ,PR 3 7 1% ,总有效率 65 7%。中位生存期为 19个月。毒副作用主要为骨髓抑制 ,白细胞减少发生率为 10 0 % ,其中Ⅲ度、Ⅳ度发生率为 71 4%。结论 MIEP方案治疗复发或难治非霍奇金淋巴瘤有效率高 ,毒性反应可耐受。

Objective To assess the antitumor efficacy and tolerance of combination chemotherapy with Mitoxantrone (MIT), Ifosphamide (IFO), Etoposide (VP-16) and Prednisone (PRED) for relapsed or stubborn non-Hodgkin's lymphoma.Methods 35 patients with relapsed or stubborn non-Hodgkin's lymphoma were treated with MIT 10 mg/m 2 on day 1 by intravenous infusion (iv), IFO 1.2 g/(m 2.d) for 4 days by iv,Mesna 400 mg every 4 hours for 3 times a day after IFO by iv, VP-16 65 mg/(m 2.d) for 4 days by iv, PRED 100 mg/d for 5 days by per oral, every 21～28 days (at least 3 cycles).Results The complete response rate was 28.6% and the partial response rate was 37.1%. The overall response rate was 65.7%. The median survival time was 19 months. The major toxicity was myelosuppression. Neutropenia was found in all treated cases, among them grade Ⅲ and Ⅳ accounted for 71.4%.Conclusions A high response rate was obtainted in relapsed or stubborn non-Hodgkin's lymphoma treated by MIT, IFO, VP-16 and PRED with tolerable toxicity.